Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan. (PubMed, Cancer Rep (Hoboken)) - Sep 13, 2026 - "The shift to long-acting GnRH formulations was associated with a reduction in injections of about one in five, even though the number of patients increased and was estimated to account for part of the reduction in drug cost. Because the oncological effect is similar among GnRH drugs, a further shift to long-acting formulations may lower the burden on patients and on health care."
HEOR • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
Akihito Hashizume; Daiji Takamoto; Hiroji Uemura; Jun-Ichi Teranishi; Kazuhide Makiyama; Masanobu Yamazaki; Takashi Kawahara; Teppei Takeshima
|